Adjuvant interferon alpha 2b in high risk melanoma - the Scottish study.

PubWeight™: 0.93‹?›

🔗 View Article (PMC 2363881)

Published in Br J Cancer on May 04, 2001


D A Cameron1, M C Cornbleet, R M Mackie, J A Hunter, M Gore, B Hancock, J F Smyth, Scottish Melanoma Group

Author Affiliations

1: Western General Hospital, Edinburgh, United Kingdom.

Articles by these authors

Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. J Clin Oncol (2000) 9.70

Suppression of intestinal polyposis in Apc delta716 knockout mice by inhibition of cyclooxygenase 2 (COX-2). Cell (1996) 7.46

Sorafenib in advanced melanoma: a Phase II randomised discontinuation trial analysis. Br J Cancer (2006) 4.93

Allogeneic bone marrow transplantation in multiple myeloma. European Group for Bone Marrow Transplantation. N Engl J Med (1991) 4.17

a controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer. Nat Med (2000) 4.15

The anticoagulation factor protein S and its relative, Gas6, are ligands for the Tyro 3/Axl family of receptor tyrosine kinases. Cell (1995) 4.13

Cardiac outcome after peripheral vascular surgery. Comparison of general and regional anesthesia. Anesthesiology (1996) 3.65

Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer. J Clin Oncol (1997) 3.61

Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease: results of a BNLI randomised trial. Lancet (1993) 3.36

Adjuvant interferon in high-risk melanoma: the AIM HIGH Study--United Kingdom Coordinating Committee on Cancer Research randomized study of adjuvant low-dose extended-duration interferon Alfa-2a in high-risk resected malignant melanoma. J Clin Oncol (2003) 3.13

Postal consent for upper gastrointestinal endoscopy. Gut (2000) 2.95

Tyro-3 family receptors are essential regulators of mammalian spermatogenesis. Nature (1999) 2.80

WWOX: a candidate tumor suppressor gene involved in multiple tumor types. Proc Natl Acad Sci U S A (2001) 2.79

A prognostic model for ovarian cancer. Br J Cancer (2001) 2.77

Sulphasalazine in rheumatoid arthritis: a double blind comparison of sulphasalazine with placebo and sodium aurothiomalate. Br Med J (Clin Res Ed) (1983) 2.63

Characterization and properties of nine human ovarian adenocarcinoma cell lines. Cancer Res (1988) 2.40

Cutaneous malignant melanoma, Scotland, 1979-89. The Scottish Melanoma Group. Lancet (1992) 2.31

Malignant melanoma in Scotland 1979-1983. Lancet (1985) 2.30

Excision biopsy of malignant melanoma by general practitioners in south east Scotland 1982-91. BMJ (1992) 2.14

Cutaneous malignant melanoma in Scotland: incidence, survival, and mortality, 1979-94. The Scottish Melanoma Group. BMJ (1997) 2.08

Antibodies to neutrophil cytoplasmic antigens: serologic marker for Sweet's syndrome. J Am Acad Dermatol (1991) 1.98

Antiprostaglandin synthetase activity of nonsteroidal anti-inflammatory drugs and gastrointestinal micro-bleeding: a comparison of flurbiprofen with benoxaprofen. Ann Rheum Dis (1981) 1.97

Systemic complement activation in psoriasis vulgaris. Clin Exp Dermatol (1996) 1.94

Tanning with ultraviolet A sunbeds. BMJ (1990) 1.93

Benign melanocytic naevi as a risk factor for malignant melanoma. Br Med J (Clin Res Ed) (1986) 1.88

Effect of disease modifying agents on the lipid profiles of patients with rheumatoid arthritis. Ann Rheum Dis (1997) 1.87

Postoperative depression of tumour-directed cell-mediated immunity in patients with malignant disease. Br Med J (1972) 1.84

Brain alpha-bungarotoxin binding protein cDNAs and MAbs reveal subtypes of this branch of the ligand-gated ion channel gene superfamily. Neuron (1990) 1.72

Does second-line therapy affect the radiological progression of rheumatoid arthritis? Ann Rheum Dis (1984) 1.69

Post-irradiation morphoea. Br J Dermatol (1989) 1.69

Lack of radiological and clinical benefit over two years of low dose prednisolone for rheumatoid arthritis: results of a randomised controlled trial. Ann Rheum Dis (2004) 1.69

Leg wound complications associated with coronary revascularization. J Thorac Cardiovasc Surg (1981) 1.67

Radio-immunoassay detection of interferon-gamma in urine after intravesical Evans BCG therapy. J Urol (1990) 1.66

Whole-genome sequencing reveals complex mechanisms of intrinsic resistance to BRAF inhibition. Ann Oncol (2014) 1.64

The human tumour xenograft--a valid model in experimental chemotherapy? Br J Surg (1980) 1.63

Predominant generation of 15-lipoxygenase metabolites of arachidonic acid by epithelial cells from human trachea. Proc Natl Acad Sci U S A (1985) 1.59

Xanthomatosis secondary to lymphoedema. Trans St Johns Hosp Dermatol Soc (1970) 1.59

A rational approach to melanoma follow-up in patients with primary cutaneous melanoma. Scottish Melanoma Group. Br J Dermatol (1999) 1.57

Circular chloroplast DNA from Euglena gracilis. Proc Natl Acad Sci U S A (1971) 1.57

Phase I trial of intraperitoneal injection of the E1B-55-kd-gene-deleted adenovirus ONYX-015 (dl1520) given on days 1 through 5 every 3 weeks in patients with recurrent/refractory epithelial ovarian cancer. J Clin Oncol (2002) 1.55

Common BRCA1 variants and susceptibility to breast and ovarian cancer in the general population. Hum Mol Genet (1997) 1.55

Incidence of and survival from malignant melanoma in Scotland: an epidemiological study. Lancet (2002) 1.53

Juvenile plantar dermatosis: a new entity?. Clin Exp Dermatol (1976) 1.51

The prognostic value of epidermal growth factor receptor mRNA expression in primary ovarian cancer. Br J Cancer (1996) 1.51

Which component of sulphasalazine is active in rheumatoid arthritis? Br Med J (Clin Res Ed) (1985) 1.51

A clinical study assessing the tolerability and biological effects of infliximab, a TNF-alpha inhibitor, in patients with advanced cancer. Ann Oncol (2008) 1.50

Effect of acetylator phenotype on efficacy and toxicity of sulphasalazine in rheumatoid arthritis. Ann Rheum Dis (1985) 1.49

Neurological abnormalities following open-heart surgery. J Thorac Cardiovasc Surg (1969) 1.48

Small-cell lung cancer after retinoblastoma. Lancet (1989) 1.48

Cellular heterogeneity and drug resistance in two ovarian adenocarcinoma cell lines derived from a single patient. Int J Cancer (1987) 1.47

Results of interleukin-2-based treatment in advanced melanoma: a case record-based analysis of 631 patients. J Clin Oncol (1998) 1.46

Contribution of BRCA1 mutations to ovarian cancer. N Engl J Med (1997) 1.44

The therapeutic response of bronchial carcinoma xenografts: a direct patient-xenograft comparison. Br J Cancer Suppl (1980) 1.44

Evaluation of the efficacy of the VEEP regimen in adult Hodgkin's disease with assessment of gonadal and cardiac toxicity. J Clin Oncol (1995) 1.43

The treatment of plantar warts in the home. A critical appraisal of a new preparation. Practitioner (1971) 1.42

Role of adenosine deaminase in lymphocyte proliferation. Clin Exp Immunol (1976) 1.41

Melanoma incidence and mortality in Scotland 1979-2003. Br J Cancer (2007) 1.41

Fluorescent lights, ultraviolet lamps, and risk of cutaneous melanoma. BMJ (1988) 1.41

A human tumour model. Lancet (1986) 1.39

Fibrin-ring granulomas: a non-specific reaction to liver injury? Histopathology (1991) 1.39

The real costs of emesis--an economic analysis of ondansetron vs. metoclopramide in controlling emesis in patients receiving chemotherapy for cancer. Eur J Cancer (1993) 1.39

Assessment of an anti-T-cell receptor variable region antibody panel in cutaneous T-cell lymphoma. Br J Dermatol (1994) 1.39

A 700-kb physical map of a region of 16q23.2 homozygously deleted in multiple cancers and spanning the common fragile site FRA16D. Cancer Res (2000) 1.39

Rupture of an otherwise normal aortic valve. Report of two cases and review of the literature. J Thorac Cardiovasc Surg (1968) 1.39

Clonal analysis of a human antibody response. Quantitation of precursors of antibody-producing cells and generation and characterization of monoclonal IgM, IgG, and IgA to rabies virus. J Exp Med (1990) 1.38

Intravesical Evans strain BCG therapy: quantitative immunohistochemical analysis of the immune response within the bladder wall. J Urol (1992) 1.38

The dermatology out-patient service: a study of out-patient referrals in a Scottish population. Br J Dermatol (1984) 1.38

The suitability of SunCheck patches and Tanscan cards for monitoring the sunburning effectiveness of sunlight. Br J Dermatol (1993) 1.38

Health and the ozone layer. BMJ (1988) 1.37

Sweet's syndrome: a clinicopathologic review of twenty-nine cases. J Am Acad Dermatol (1990) 1.36

UVA-induced melanocytic lesions. Br J Dermatol (1987) 1.35

Structural and immunological characterization of a linear virus-neutralizing epitope of the rabies virus glycoprotein and its possible use in a synthetic vaccine. J Virol (1990) 1.35

Human papilloma virus infection and skin cancer in renal allograft recipients. Lancet (1989) 1.34

Community acquired pneumonia: aetiology and prognostic index evaluation. Thorax (1991) 1.34

A case of primary choriocarcinoma of the fallopian tube. J Obstet Gynaecol (2010) 1.33

Topotecan, an active drug in the second-line treatment of epithelial ovarian cancer: results of a large European phase II study. J Clin Oncol (1996) 1.33

A phase I study of the safety and tolerability of olaparib (AZD2281, KU0059436) and dacarbazine in patients with advanced solid tumours. Br J Cancer (2011) 1.31

Sulphasalazine in the treatment of rheumatoid arthritis: relationship of dose and serum levels to efficacy. Br J Rheumatol (1985) 1.30

Effect of sulphasalazine on the radiological progression of rheumatoid arthritis. Ann Rheum Dis (1987) 1.29

Remission induction with adenosine-deaminase inhibitor 2'-deoxycoformycin in Thy-lymphoblastic leukaemia. Lancet (1980) 1.29

Tamoxifen as primary treatment of breast cancer in elderly or frail patients: a practical management. Br Med J (Clin Res Ed) (1985) 1.29

Seventeen-year experience with routine shunting in carotid artery surgery. World J Surg (1979) 1.28

Chemotherapy in advanced ovarian cancer: four systematic meta-analyses of individual patient data from 37 randomized trials. Advanced Ovarian Cancer Trialists' Group. Br J Cancer (1998) 1.27

Induction of rabies virus-specific T-helper cells by synthetic peptides that carry dominant T-helper cell epitopes of the viral ribonucleoprotein. J Virol (1989) 1.27

The impact of chemotherapy on small cell carcinoma of the bronchus. Q J Med (1986) 1.26

Adaptations of glutathione antioxidant system to endurance training are tissue and muscle fiber specific. Am J Physiol (1997) 1.25

Monoclonal antibodies and human tumor pathology. Hum Pathol (1982) 1.24

Structure, expression, and activity of Tyro 3, a neural adhesion-related receptor tyrosine kinase. Oncogene (1994) 1.24

En bloc resection of colon cancer adherent to other organs. Am J Surg (1987) 1.23

A neutral protease in rheumatoid synovial fluid capable of attacking the telopeptide regions of polymeric collagen fibrils. Biochim Biophys Acta (1975) 1.23

Targeted anti-vascular therapies for ovarian cancer: current evidence. Br J Cancer (2013) 1.21

Superoxide dismutase gene expression is activated by a single bout of exercise in rat skeletal muscle. Pflugers Arch (2001) 1.20

Biological characterization of human monoclonal antibodies to rabies virus. J Virol (1990) 1.20

Adenosine deaminase activity in leukaemia. Br J Cancer (1975) 1.19

Chemotherapy for ovarian cancer--a consensus statement on standard practice. Br J Cancer (1998) 1.19

DNA topoisomerase I and II as targets for rational design of new anticancer drugs. Ann Oncol (1993) 1.19

Giant hogweed dermatitis. Scott Med J (1970) 1.19

Synthesis of macromolecules during induction of haemoglobin synthesis by erythropoietin. J Mol Biol (1969) 1.18